Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Jun 13, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, press-release
TL;DR
Innate Pharma filed a 6-K on 6/13/25, likely with a press release. Standard update.
AI Summary
Innate Pharma SA filed a Form 6-K on June 13, 2025, reporting a press release dated the same day. The company is a French biotechnology firm specializing in biological products, with its principal executive office located in Marseille, France. This filing indicates ongoing reporting requirements for the company as a foreign private issuer.
Why It Matters
This filing serves as an update for investors and stakeholders regarding Innate Pharma's regulatory compliance and ongoing corporate activities as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine 6-K filing, typically used by foreign private issuers for reporting material events or press releases, and does not inherently signal significant new risks.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- June 13, 2025 (date) — Filing Date
- Marseille, France (location) — Principal Executive Office
- 001-39084 (other) — SEC File Number
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, have filed or are required to file with a stock exchange, or have distributed or are required to distribute to their security holders.
What specific information is included in this 6-K filing?
This 6-K filing specifically includes Exhibit 99.1, which is a Press Release dated June 13, 2025.
What is Innate Pharma's primary business?
Innate Pharma SA is primarily involved in the business of Biological Products (excluding diagnostic substances), as indicated by its SIC code [2836].
Where is Innate Pharma's principal executive office located?
Innate Pharma's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Is Innate Pharma required to file annual reports under Form 20-F?
Yes, Innate Pharma indicates with a checkmark that it files or will file annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 13, 2025 regarding Innate Pharma SA (IPHYF).